Alkermes' Q3 Proprietary Sales Soar 18%
The biopharma company's third-quarter report highlighted robust proprietary product performance, despite some weakness ...
Alkermes upgraded to Buy from Hold at Stifel
Stifel analyst Paul Matteis upgraded Alkermes (ALKS) to Buy from Hold with a price target of $36, up from $25. Published first on TheFly ...
Alkermes (NASDAQ:ALKS) Price Target Cut to $30.00
Alkermes (NASDAQ:ALKS – Get Free Report) had its target price dropped by equities researchers at The Goldman Sachs Group from ...
Nasdaq12d
Alkermes price target lowered to $43 from $48 at Cantor Fitzgerald
Cantor Fitzgerald lowered the firm’s price target on Alkermes (ALKS) to $43 from $48 and keeps an Overweight rating on the shares. Alkermes reported Q3 revenues below consensus estimates but in ...
Seeking Alpha13d
Alkermes plc (ALKS) Q3 2024 Earnings Call Transcript
Greetings and welcome to the Alkermes' Third Quarter 2024 Financial Results Conference Call. My name is Maria and I'll be your operator for today's call. All participant lines will be placed on ...
ETF Daily News10d
Alkermes (NASDAQ:ALKS) Rating Reiterated by Piper Sandler
Alkermes (NASDAQ:ALKS – Get Free Report)‘s stock had its “overweight” rating reiterated by equities researchers at Piper ...
PR Newswire13d
Alkermes plc Reports Third Quarter 2024 Financial Results
Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on ...
A Look Ahead: Ultragenyx Pharmaceutical's Earnings Forecast
The consensus rating for Ultragenyx Pharmaceutical is Outperform, based on 6 analyst ratings. With an average one-year price target of $102.33, there's a potential 100.69% upside.